Intraperitoneal Paclitaxel for Metastatic Appendiceal Adenocarcinoma
This study is testing a treatment called paclitaxel, given directly into the belly (intraperitoneal), for people with appendiceal adenocarcinoma that has spread (metastatic) and cannot be removed by surgery. The main goals are to find the safest dose of paclitaxel and to see how well it shrinks tumors. You might be able to join if you are 18 or older, have metastatic appendiceal adenocarcinoma in your belly, and are not able to have surgery. The study is looking for 39 participants and is currently unclear if it is recruiting.
- Study design
- This is a Phase I/II interventional study, meaning it will first look for the best dose and then study how well the treatment works. It plans to enroll 39 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety and side effects will be monitored throughout the study, which is expected to last an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Beth Helmink, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and adverse events (AEs)Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0